Skip to main content

Table 3 Multivariate logistic regression results for characteristics associated with raloxifene vs. bisphosphonate use

From: Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates

  Commercial/Medicare Medicaid
  Odds Ratio1 95% CI Odds Ratio1 95% CI
Age group     
45–64 0.881 0.810–0.957 1.509 1.431–1.592
65–74 REFERENCE --- REFERENCE ---
75 and over 0.686 0.644–0.730 0.813 0.774–0.854
Race     
White --- --- REFERENCE ---
African American --- --- 1.025 0.933–1.126
Hispanic/Latino --- --- 1.070 1.005–1.140
Asian --- --- 1.758 1.665–1.856
Other --- --- 1.299 1.220–1.382
Medicare 0.689 0.630–0.754 --- ---
Location     
North East 0.672 0.629–0.718 --- ---
North Central 0.935 0.898–0.973 --- ---
South REFERENCE --- --- ---
West 0.642 0.609–0.678 --- ---
Urban residence 0.819 0.788–0.851 0.667 0.611–0.706
Insurance type     
Indemnity 0.986 0.935–1.040 1.128 1.068–1.192
PPO 1.031 0.985–1.079 --- ---
Other REFERENCE --- REFERENCE ---
Provider specialty     
Primary care/Other REFERENCE --- REFERENCE ---
Specialist 1.108 1.060–1.158 1.264 1.160–1.377
Health status     
CCI 0.941 0.926–0.957 0.962 0.948–0.976
Fracture     
Hip 0.449 0.350–0.577 0.659 0.507–0.856
Vertebral 0.664 0.580–0.762 0.744 0.631–0.876
Non-vertebral 0.803 0.758–0.851 0.726 0.674–0.781
BMD test 0.412 0.398–0.426 0.664 0.628–0.703
Mammogram 0.968 0.909–1.031 0.953 0.886–1.026
Confounding conditions     
Breast cancer 0.746 0.679–0.819 1.021 0.928–1.123
DVT/PE 0.470 0.245–0.903 0.672 0.438–1.028
Gastric ulcer 2.273 1.181–4.375 0.861 0.585–1.267
Peptic ulcer 2.048 0.964–4.353 1.228 0.942–1.601
Dysphagia 0.974 0.694–1.367 1.200 0.917–1.571
Reflux 1.080 0.897–1.300 1.156 1.005–1.329
Gastritis 0.904 0.666–1.228 1.316 1.156–1.499
Osteoporosis 0.632 0.573–0.697 0.818 0.745–0.898
Medications     
Glucocorticoids 0.774 0.737–0.813 0.757 0.713–0.804
Estrogen/HRT 1.325 1.279–1.372 1.501 1.426–1.581
  1. 1Odds ratios that are less than 1.0 indicate that the covariate is associated with a lower likelihood of receiving raloxifene (or is associated with equivalently a higher likelihood of receiving a bisphosphonate). Odds ratios greater than 1.0 indicate that the covariate is associated with a higher likelihood of receiving raloxifene.